ライフサイエンスコーパス: administered subcutaneously

1 th infectious H. pylori when the vaccine was administered subcutaneously.

2 a in both hotplate and tail-flick tests when administered subcutaneously.

3 ment of seasonal allergic rhinitis is 300 mg administered subcutaneously.

4 (n = 6), 300 mg (n = 6), or 600 mg (n = 6), administered subcutaneously.

5 mg, 12 mg, 32 mg, 96 mg, 304 mg, or 608 mg) administered subcutaneously.

6 group (adalimumab 40 mg every 2 weeks), all administered subcutaneously.

7 225 mg every 24 weeks) or matching placebo, administered subcutaneously.

8 Since the first attempts, AIT was administered subcutaneously.

9 distinct inactivated bacterial-based stimuli administered subcutaneously.

10 ritoneally are highly protective, as is H84T administered subcutaneously.

11 more efficient than mRNA nanoparticles when administered subcutaneously.

12 cterium bovis bacillus Calmette-Guerin (BCG) administered subcutaneously.

13 From course 2 onward, HDI maintenance was administered subcutaneously.

14 cental growth factor with high affinity, was administered subcutaneously.

15 5-AC is rapidly absorbed and eliminated when administered subcutaneously.

16 ys 1, 8, and 15, with IL-2 (6 million units) administered subcutaneously 2-4 h after each FT516 dose.

17 n=11) or saline (n=10) at a dose of 10 mg/kg administered subcutaneously 24-h after stroke and daily

18 wth and development factor (PEG-rHuMGDF) was administered subcutaneously (25 microg/kg twice weekly f

19 al trial of 16 weeks of 250 microg of GM-CSF administered subcutaneously 3 times/week, followed by op

20 eatment was stabilized with morphine, 30 mg, administered subcutaneously 4 times daily.

21 evelopment factor (PEG-rHuMGDF) or a placebo administered subcutaneously after completion of chemothe

22 When administered subcutaneously, ALN-AT3 showed potent, dose

23 d pharmacokinetics of VRC07-523LS and PGT121 administered subcutaneously alone and in combination as

24 irus (HCV) infection is interferon, which is administered subcutaneously and can have troublesome sid

25 vable in-situ forming implant (ISFI) that is administered subcutaneously and can release the integras

26 the kidney and inhibit miR-21 function when administered subcutaneously and evaluated the therapeuti

27 s with RAD (everolimus) (0.075 mg/kg per day administered subcutaneously) and FTY720 (0.3 mg/kg per d

28 ee or four doses of 2.5 mg/kg MPTP free base administered subcutaneously at 2-h intervals.

29 The Rbm20-ASOs were administered subcutaneously at 25 mg/kg once a week for

30 Thymosin alpha 1 was administered subcutaneously at 400 microgram/m2 after fo

31 KL was administered subcutaneously at 50 microg/kg, 21 hours an

32 Etanercept was administered subcutaneously at a dose of 0.4 mg/kg (maxi

33 ha was performed using etanercept, which was administered subcutaneously at a dose of 0.5 mg/kg aroun

34 rhIL-12 was initially administered subcutaneously at a dose of 100 ng/kg, wher

35 ultiple sclerosis to compare daclizumab HYP, administered subcutaneously at a dose of 150 mg every 4

36 Etanercept was administered subcutaneously at a dose of 25 mg twice wee

37 Galcanezumab administered subcutaneously at a dose of 300 mg once mon

38 5 mg twice daily for 30 days, or enoxaparin, administered subcutaneously at a dose of 40 mg once dail

39 In group A (n = 24), bermekimab was administered subcutaneously at a dose of 400 mg weekly (

40 therapy; in group B (n = 18), bermekimab was administered subcutaneously at a dose of 400 mg weekly (

41 5-AZA was administered subcutaneously at a fixed dose of 75 mg/m(2

42 Erenumab administered subcutaneously at a monthly dose of 70 mg o

43 lcanezumab (at a dose of 300 mg) or placebo, administered subcutaneously at baseline and at 1 month.

44 dose of 0.5 mg per kilogram of body weight) administered subcutaneously at baseline, week 4, and wee

45 300 mg secukinumab was administered subcutaneously at baseline, weeks 1, 2, 3,

46 Both antipsychotics were administered subcutaneously at behaviorally effective do

47 AM0010 was self-administered subcutaneously at doses of 1 to 40 mug/kg o

48 GI2 synthase inhibitor, tranylcypromine, was administered subcutaneously at the time of CLP and again

49 Tildrakizumab was administered subcutaneously at weeks 0 and 4 during part

50 (at a dose of 50, 150, or 450 mg) or placebo administered subcutaneously at weeks 0, 2, 4, 8, 12, 16,

51 enoceptor antagonist propranolol (2.0 mg/kg) administered subcutaneously before retention testing did

52 nts also received filgrastim 5 micrograms/kg administered subcutaneously beginning on day 2 and conti

53 ovided in single-use 3 mL vials and was self-administered subcutaneously by injection at home at 10 m

54 The vaccine was administered subcutaneously by nurses who were not maske

55 og of parathyroid hormone (1-34) or placebo, administered subcutaneously by the women daily.

56 Whether a monoclonal antibody administered subcutaneously can protect children from P.

57 The MTD of rhuCD40L when administered subcutaneously daily for 5 days was defined

58 ge colony-stimulating factor 250 microg/m(2) administered subcutaneously daily.

59 s administered IV (days 2-5), and GM-CSF was administered subcutaneously (days 6-12).

60 GM-CSF (250 mug/m2/d) or placebo were administered subcutaneously (double-blinded) 3 times/wk

61 Five vaccinations were administered subcutaneously during 26 weeks with an addi

62 one (25 mg/kg of body weight) or vehicle was administered subcutaneously during resuscitation.

63 effects of benralizumab (at a dose of 30 mg administered subcutaneously either every 4 weeks or ever

64 ative properties of linezolid and vancomycin administered subcutaneously every 12 hours.

65 Omalizumab was administered subcutaneously every 2 or 4 weeks based on

66 1800-mg loading dose), 300 mg of frexalimab administered subcutaneously every 2 weeks (with a 600-mg

67 ase, double-blind study of alirocumab 150 mg administered subcutaneously every 2 weeks to 13 patients

68 sed system to receive adalimumab or placebo, administered subcutaneously every 2 weeks until the 48-w

69 Alirocumab 75 mg or placebo was administered subcutaneously every 2 weeks.

70 f 500 mg at baseline and week 2) or placebo, administered subcutaneously every 2 weeks.

71 40 mg, according to body weight) or placebo, administered subcutaneously every 2 weeks.

72 DCVAC/PCa or placebo was administered subcutaneously every 3 to 4 weeks (up to 15

73 mg per kilogram of body weight) or placebo, administered subcutaneously every 3 weeks.

74 Denosumab was administered subcutaneously every 4 weeks (30, 120, or 1

75 b (at a dose of 100 mg) with that of placebo administered subcutaneously every 4 weeks for 20 weeks.

76 mg, 200 mg, or 400 mg or to receive placebo, administered subcutaneously every 4 weeks for three dose

77 kg lebrikizumab (n = 13) or placebo (n = 16) administered subcutaneously every 4 weeks over 12 weeks,

78 Omalizumab 300 mg administered subcutaneously every 4 weeks reduced weekly

79 Golimumab, administered subcutaneously every 4 weeks, has been show

80 to receive 300 mg of mepolizumab or placebo, administered subcutaneously every 4 weeks, plus standard

81 Vixarelimab and placebo were administered subcutaneously every 4 weeks.

82 o AMG 145 350 mg, AMG 145 420 mg, or placebo-administered subcutaneously every 4 weeks.

83 AMG145 or placebo was administered subcutaneously every 4 weeks.

84 Golimumab orplacebo was administered subcutaneously every 4 weeks.

85 to receive either denosumab 60 mg or placebo administered subcutaneously every 6 months in 58 trial c

86 oximately 50% were obtained with inclisiran, administered subcutaneously every 6 months.

87 imumab at a dosage of 20 mg, 40 mg, or 80 mg administered subcutaneously every other week to long-ter

88 al antibody therapy targeted to PCSK9 may be administered subcutaneously every two or four weeks.

89 In patients with IgAN, zigakibart 600 mg, administered subcutaneously every two weeks, was well to

90 to receive mirikizumab (200 mg) or placebo, administered subcutaneously, every 4 weeks for 40 weeks.

91 Omalizumab or placebo was administered subcutaneously for 16 weeks, with oral immu

92 f IL-2 from 62,500 to 250,000 IU/m2/day were administered subcutaneously for 6 months to 16 HIV+ indi

93 RhML was administered subcutaneously for 8 weeks to three normal

94 PIXY321 was administered subcutaneously in 2 divided doses.

95 performed a dose-escalation study of MVA-BN administered subcutaneously in 2 doses, one on day 0 and

96 The GM-CSF was administered subcutaneously in 28-day cycles, such that

97 ice a day [200 mg], n = 46), which were self-administered subcutaneously in 28-day treatment periods.

98 MTX was administered subcutaneously in 66 patients (67%).

99 us toxoid (TT) or diphtheria toxoid (DT) and administered subcutaneously in Alhydrogel with or withou

100 c)-D4Aph(Ac)-Leu-ILys-Pro-DAla-NH2] (6) when administered subcutaneously in castrated male rats at a

101 s proof of concept for a monoclonal antibody administered subcutaneously in HIV-1 infected individual

102 blind, placebo-controlled trial with Alt a 1 administered subcutaneously in patients with allergic rh

103 Epcoritamab was administered subcutaneously in step-up doses followed by

104 sulin peptides B:9-23 and B:13-23, even when administered subcutaneously in the absence of adjuvant,

105 , 75 mug, or 100 mug per day of rhPTH(1-84), administered subcutaneously in the outpatient setting, i

106 San Jose, CA) loaded with 9-cis retinal was administered subcutaneously into Rpe65(-/-) mouse pups f

107 Drugs were administered subcutaneously, LY235959 at doses of 0.5, 1

108 Administered subcutaneously, [N(epsilon)-palmitoyl Lys(B

109 (OVA group) plus Complete Freund's Adjuvant administered subcutaneously on day 0 followed by OVA nas

110 d fashion to receive octreotide (100 microg, administered subcutaneously on day 1, followed by depot

111 nsplants with two 30-mg doses of alemtuzumab administered subcutaneously on days 0 and 1.

112 ltured in the presence of F573, and F573 was administered subcutaneously on days 0 to 5 posttransplan

113 8-day cycles, with LDAC (20 mg/m(2) per day) administered subcutaneously on days 1 to 10.

114 REGN727 doses of 50, 100, or 150 mg were administered subcutaneously on days 1, 29, and 43.

115 CMVPepVax was administered subcutaneously on days 28 and 56.

116 Epoetin alfa was administered subcutaneously once a week starting at 450

117 Antibiotics were administered subcutaneously once daily at 12 mg/kg, for

118 enous dose or to receive 40 mg of enoxaparin administered subcutaneously once daily.

119 wice daily (104), adalimumab at a 40-mg dose administered subcutaneously once every 2 weeks (106), pl

120 to luspatercept (1.0-1.25 mg/kg) or placebo administered subcutaneously once every 21 days.

121 Luspatercept was administered subcutaneously once every 3 weeks starting

122 to receive 90 mg of risankizumab or placebo, administered subcutaneously once every 4 weeks.

123 Low-molecular-weight heparins administered subcutaneously once or twice daily have bee

124 d gout were randomized to receive rilonacept administered subcutaneously once per week (loading dose

125 -mg, 50-mg or 100-mg volenrelaxin or placebo administered subcutaneously once weekly.

126 continued rilonacept monotherapy or placebo, administered subcutaneously once weekly.

127 Azacitidine (75 mg/m(2)) was administered subcutaneously or intravenously daily for 7

128 -mediated tumor burden in C57BL/6J mice when administered subcutaneously or orally.

129 ered intramyocardially), 5 mg/kg of AMD3100 (administered subcutaneously), or both; cardiac function

130 y occlusion model in rats, clomethiazole was administered subcutaneously over 22.75 h using osmotic m

131 DHEA was administered subcutaneously prior to arthritis induction

132 n mice), H84T BanLec reduced VZV spread when administered subcutaneously prior to intraxenograft viru

133 ecombinant human erythropoietin (epoetin) is administered subcutaneously rather than intravenously, a

134 by 3 orders of magnitude when the strain was administered subcutaneously (s.c.).

135 ranging from 1.0 x 10(3) to 1.0 x 10(5) PFU administered subcutaneously (s.c.).

136 Filgrastim (5 micrograms/kg/d) was administered subcutaneously (SC) beginning on day 2 of e

137 on day 1 of every cycle or degarelix 240 mg administered subcutaneously (SC) on day 1 of cycle 1 the

138 ose of house dust mite PM-allergoid (PM-HDM) administered subcutaneously (SC) or sublingually (SL).

139 It can be administered subcutaneously (SCIT) or sublingually (SLIT

140 581) or insulin on a sliding scale that was administered subcutaneously (target blood glucose concen

141 lizing formulation and were more active when administered subcutaneously than orally, both of which s

142 When administered subcutaneously, the nano-suspension formed

143 mechanical and thermal hypersensitivity when administered subcutaneously; this response abrogated by

144 ]-(S)-phenylglycine t-butyl ester; DAPT) was administered subcutaneously three times a week starting

145 regimen followed by IFN-alpha-2b 10 MIU/m(2) administered subcutaneously three times per week for 48

146 ombined with IFN (6 or 9 million units [MU]) administered subcutaneously three times per week.

147 of BSR (0.15 mg/kg) and EXR (0.1-0.2 mg/kg) administered subcutaneously to adult marmosets.

148 A whole-cell T. vaginalis vaccine was administered subcutaneously to BALB/c mice, using a prim

149 MEDI0618 was administered subcutaneously to C57BL6/J female mice prio

150 G-CSF or 5% dextrose in water was administered subcutaneously to cirrhotic and control rat

151 olycaspase inhibitor IDN-1965 or vehicle was administered subcutaneously to Galpha(q) mice by osmotic

152 AV513 administered subcutaneously to low-FVIII dogs for multip

153 with a Ribi- or saponin-type adjuvant, were administered subcutaneously to mice.

154 When administered subcutaneously to NOD mice, this peptide de

155 V-B phototherapy, 16 mg of afamelanotide was administered subcutaneously to the combination therapy g

156 eceive inactivated-poliovirus vaccine (IPV), administered subcutaneously; trivalent OPV manufactured

157 Recombinant leptin was administered subcutaneously twice a day for four months

158 lating factor (G-CSF; 250 microg/kg/day) was administered subcutaneously twice daily on days 3 to 6 a

159 kilogram of body weight) or matching placebo administered subcutaneously twice daily, from 3 days bef

160 weight heparin) per kilogram of body weight, administered subcutaneously twice daily, or continuous i

161 IL-12 was administered subcutaneously twice weekly at doses from 1

162 s received etanercept (0.4 mg/kg) or placebo administered subcutaneously twice weekly for 6 months.

163 Atacicept administered subcutaneously was well tolerated and demon

164 VRC07-523LS and PGT121, administered subcutaneously, were safe and well tolerate

165 indings also that indicate PIV5-RSV F may be administered subcutaneously, which is the preferred rout

166 ivery system, tailored for lymphatic uptake, administered subcutaneously, will have decreased drug re

167 2:1 ratio, to receive omalizumab or placebo administered subcutaneously (with the dose based on weig

168 temic immunoglobulin G (IgG) antibodies when administered subcutaneously without an additional adjuva

169 avenously, but is much better tolerated when administered subcutaneously without loss of therapeutic